McCarthy M W
Weill Cornell Medical College, New York, New York, USA.
Drugs Today (Barc). 2020 Mar;56(3):177-184. doi: 10.1358/dot.2020.56.3.3118466.
On November 14, 2019, the U.S. Food and Drug Administration (FDA) approved cefiderocol, a siderophore-cephalosporin conjugate antibiotic, for the treatment of adults with complicated urinary tract infections (cUTIs), including kidney infections caused by susceptible Gram-negative microorganisms, who have limited or no alternative treatment options. The approval was based on substantial preclinical and clinical data, including in vitro and in vivo work, as well as pharmacokinetic and pharmacodynamic studies that established cefiderocol as an effective agent for the treatment of cUTI. This paper reviews that work and looks ahead to determine how cefiderocol might be used by clinicians in the future.
2019年11月14日，美国食品药品监督管理局（FDA）批准了头孢地尔，一种铁载体-头孢菌素缀合抗生素，用于治疗患有复杂性尿路感染（cUTIs）的成人，包括由易感革兰氏阴性微生物引起的肾脏感染，这些患者的治疗选择有限或没有其他选择。该批准基于大量的临床前和临床数据，包括体外和体内研究，以及药代动力学和药效学研究，这些研究确定头孢地尔是治疗cUTI的有效药物。本文回顾了这些研究工作，并展望未来以确定临床医生未来可能如何使用头孢地尔。
